LinkedIn Profile

Access Rgenix historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:rgenix 2798720 May 31st, 2019 12:00AM Rgenix, Inc. 457 15.00 Open Biotechnology May 31st, 2019 11:32AM May 31st, 2019 11:32AM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Open Cancer, Drug Discovery, First in class therapies, RGX-104, microRNA Open 310 E 67th Street, Suite 1-12 New York NY US 10065 Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 17th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 16th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 15th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 14th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 13th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 12th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 11th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 10th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology
private:rgenix 2798720 Feb 9th, 2018 12:00AM Rgenix, Inc. 276 14.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM Rgenix is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016. Rgenix Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.